Ingen appoints director of r&d
Aims to increase sales of in vitro diagnostic (IVD) kits
Mignon-Godefroy joins the firm to generate sales of its first proprietary in vitro diagnostic (IVD) kit. These IVD kits are based on the firm’s specialist knowledge in proteomics and expertise in synthesising new recombinant antigens. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.
‘Dr Mignon-Godefroy’s 15 years’ experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going r&d efforts,’ said Jean-Pierre Hermet, chief executive of Ingen Biosciences. ‘Her arrival will also strengthen the team, which has made significant inroads into developing products based on innovative technologies.'
Mignon-Godefroy joins Ingen Biosciences from the blood virus division of Bio-Rad, a manufacturer and distributor of products for a range of technologies including proteomics, where she was director of international projects.
You may also like
Manufacturing
Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks
Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and
other highly regulated industries
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2